advertisement
Abstract #25891 Published in IGR 12-2
First-year treatment costs among new initiators of topical prostaglandin analogs: Pooled results
Schmier JK; Covert DWClinical Ophthalmology 2010; 4: 437-445
Objective: To estimate first-year treatment costs among new initiators of topical prostaglandin analogs in a managed care population. Research design and methods: A model was developed to estimate first-year medical costs. Model inputs were based on weighted results from three previous studies. Treatment patterns were derived from a claims database analysis. Published studies were used to estimate visit-related resource use. Costs were obtained from standard sources. Results: Across studies, 27,809 patients met study criteria, 44.2% of whom remained on their index therapy for 12 months. Adjunctive therapy was needed in 22.5%, 18.5%, and 11.9% of bimatoprost, latanoprost, and benzalkonium chloride (BAK)-free travoprost patients, respectively. Median days to initiating adjunctive therapy were 64, 67, and 127 for bimatoprost, latanoprost, and BAK-free travoprost patients. Estimated first-year medical costs were $1,945, $1,803, and $1,730 for patients initiating therapy with bimatoprost, latanoprost, and BAK-free travoprost. Findings were consistent through sensitivity analysis. Conclusions: A BAK-free prostaglandin analog may permit longer duration of monotherapy and be associated with lower first-year treatment costs. Use of a claims database and the selection of new initiators of prostaglandin analogs limit the ability to project findings to all glaucoma patients.
J. K. Schmier. 1800 Diagonal Rd, Suite 300, Alexandria, VA 22314, United States. jschmier@exponent.com
Classification:
14 Costing studies; pharmacoeconomics
11.4 Prostaglandins (Part of: 11 Medical treatment)
